Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Northwest Biotherapeutics (NWBO) EBIAT (2016 - 2025)

Northwest Biotherapeutics' EBIAT history spans 16 years, with the latest figure at $1.4 million for Q4 2025.

  • Quarterly results put EBIAT at $1.4 million for Q4 2025, up 104.92% from a year ago — trailing twelve months through Dec 2025 was -$60.2 million (up 28.19% YoY), and the annual figure for FY2025 was -$60.2 million, up 28.19%.
  • EBIAT for Q4 2025 was $1.4 million at Northwest Biotherapeutics, up from -$26.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $133.3 million in Q4 2021 to a low of -$32.9 million in Q3 2022.
  • The 5-year median for EBIAT is -$16.6 million (2024), against an average of -$6.6 million.
  • The sharpest move saw EBIAT soared 147.56% in 2021, then tumbled 772.74% in 2022.
  • Year by year, EBIAT stood at $133.3 million in 2021, then plummeted by 121.23% to -$28.3 million in 2022, then skyrocketed by 50.61% to -$14.0 million in 2023, then crashed by 101.92% to -$28.2 million in 2024, then surged by 104.92% to $1.4 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at $1.4 million, -$26.8 million, and -$15.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.